Clinical Trial

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Our center plans to conduct a prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with Anlotinib and Benmelstobart in the treatment of HR+/HER2- breast cancer. The aim is to further explore the treatment strategy of chemotherapy de-escalation for patients with HR+/HER2- breast cancer, provide more treatment options for breast cancer patients, and offer a potential theoretical basis for the precision treatment of breast cancer.The primary study objective is to evaluate the pathologic complete response（PCR）and RCB0-1 ratio of neodjuvant treatment of HR+/HER2- breast cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-10; most recent amendment 2025-08-11.
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT06874933
Lead Sponsor First Affiliated Hospital of Zhejiang University
Conditions HR+/HER2- Breast Cancer
Enrollment 35 participants
Start Date 2025-05-04
Primary Completion 2027-04-01 (estimated)
Study Completion 2030-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-12